Market Spotlight: Idiopathic Pulmonary Fibrosis
Disease Overview
Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease in which scarring and
thickening of the lung tissue occurs due to unknown causes. In turn, this fibrosis reduces
the ability of alveoli to transport oxygen from the lungs to the bloodstream, and results in
symptoms such as dyspnea, chronic dry cough, fatigue, and weight loss. While lung function
and capacity steadily decline in most IPF patients, some experience a sudden, rapid
increase in irreversible disease progression called acute exacerbation. The prognosis of
patients with IPF remains poor as those who are ineligible for lung transplantation have few
effective treatment options.
Market Snapshot
The size of the IPF market is set to expand significantly due to the growth of Esbriet and
Ofev in the US.
Treatment of IPF is evolving as mounting evidence and revised international guidelines
support clinical decision-making.
By 2035, Datamonitor Healthcare estimates that approximately 101,060 cases of IPF will be
diagnosed annually in these markets. As IPF disproportionately affects the elderly, aging
populations in these markets will be responsible for the largest increases in IPF.
Safety and efficacy of Esbriet and Ofev are comparable, but a few small advantages will
help Esbriet remain the market-leading therapy.
The design of clinical trials continues to standardize as pipeline drugs seek to reverse
disease progression.
Exclusive Sample Report @
https://www.reportsworldwide.com/enquiry?report_id=42616
Major TOC Market:
FORECAST: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)
EXECUTIVE SUMMARY
RECENT FORECAST UPDATES
MARKET DYNAMICS
FORECAST AND FUTURE TRENDS
MARKET DEFINITION AND METHODOLOGY
PRIMARY RESEARCH METHODOLOGY
BIBLIOGRAPHY
PRODUCT PROFILE: ESBRIET
PRODUCT PROFILE: OFEV
TREATMENT: IDIOPATHIC PULMONARY FIBROSIS (Published on 06 November 2017)
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
CURRENT TREATMENT OPTIONS
PRESCRIBING TRENDS
EPIDEMIOLOGY: IDIOPATHIC PULMONARY FIBROSIS (Published on 10 February 2016)